Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | KLK7 | P49862 | 2/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | CDC25B | P30305 | 3/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6721610 | 1.00 | PPARA (0.54) | PPARACACNA1BPPARGCTSSKLK7 | |
| SCHEMBL4281227 | 0.90 | CTSS (0.46) | PPARACACNA1BPPARGCTSSKLK5 | |
| SCHEMBL12520690 | 0.90 | CTSS (0.46) | PPARACACNA1BPPARGCTSSKLK5 | |
| SCHEMBL12520691 | 0.90 | CTSS (0.46) | PPARACACNA1BPPARGCTSSKLK5 | |
| SCHEMBL5369794 | 0.86 | CACNA1B (0.51) | PPARACACNA1BCTSSPTPN1MEN1 | |
| SCHEMBL20487177 | 0.85 | PPARA (0.56) | PPARAPPARGCTSSKLK7KLK5 | |
| SCHEMBL20487176 | 0.85 | PPARA (0.56) | PPARAPPARGCTSSKLK7KLK5 | |
| SCHEMBL26869285 | 0.84 | CTSS (0.49) | PPARAPPARGCTSSCTSLCTSB | |
| SCHEMBL23512578 | 0.83 | KLK7 (0.51) | PPARACACNA1BCTSSKLK7KLK5 | |
| SCHEMBL29528466 | 0.83 | KLK7 (0.51) | PPARACACNA1BCTSSKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | PPARA 1672/4885CACNA1B 730/4885PPARG 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.